Team Grant : Preparation to Trial: Inflammation for Chronic Conditions – LOI
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with your unit
Memorial Deadline: No RGCS review for the LOI
External Deadline: Thursday 2nd, July 2020
Description
SIRI will be offering support with application development for this opportunity. Prospective applicants are encouraged to contact Jennifer Stevens (v5js@mun.ca) early during the development process to discuss the services available to them.
A state of prolonged inflammation has been associated with many chronic health conditions, including, but not limited to cancer, diabetes, metabolic syndrome, stroke, dementia, rheumatoid arthritis, atopic dermatitis, psoriasis, inflammatory bowel disease, asthma, allergies, kidney and liver diseases, neurodegenerative diseases, infectious diseases such as HIV/AIDS and chronic obstructive lung disease. It plays a role in the development of psychiatric morbidities, including anxiety and depression, and the progression and complications of premature aging and frailty. Although the early immune or metabolic events that trigger inflammation are often specific to a given condition, they can activate shared mechanistic pathways of inflammation that lead to the development of symptoms and co-morbidities shared among chronic conditions. The advancement of knowledge in disease-specific fields has led to the development of therapies to control inflammation in specific conditions once diseases have been diagnosed. Control of inflammation can also be a strategy for prevention of chronic conditions as inflammation underlies the development of many of these conditions. Leveraging our collective understanding of inflammation mechanisms and commonalities across chronic conditions will help address a critical gap in the development of interventions and the clinical translation of research to improve prevention, diagnosis, and management of inflammation. Adoption of existing, evidence-based interventions using effective and transferable implementation strategies to optimize the delivery of healthcare is also needed to improve health outcomes for people living with or at risk of developing chronic conditions.
Therefore, the purpose of Health Challenge in Chronic Inflammation Phase 2 (HCCI2) is to support a collaborative and interdisciplinary strategy on inflammation to accelerate the development of solutions for the prevention, diagnosis, prediction of treatment response, and management of inflammation in chronic conditions through:
- the development of new solutions; and/or
- the repurposing and optimization of existing solutions.
Building on the shared framework for inflammation research initiated through prior CIHR investments (HCCI Phase 1), HCCI2 is comprised of two distinct funding opportunities that together will accelerate the clinical translation of solutions that target shared pathways of inflammation in chronic conditions.
- The first component of the HCCI2 initiative, the Preparation to Trial Funding Opportunity, will support the advancement of preclinical research towards the human intervention trial stage and/or a better understanding of the implementation context to enable the scale up of existing interventions.
- The second component (launch anticipated in 2022) will support human intervention trials with clinical impact on inflammation in chronic conditions.
The overall vision of HCCI2 is to improve the health outcomes of people living with, or at risk of developing, chronic conditions by advancing the repurposing, development and optimization of innovative interventions. Interventions are to target biological (e.g. genetic, epigenetic), environmental (e.g. exposure to chemical products), social (e.g. socioeconomic status, education) and behavioral (e.g. tobacco or cannabis smoking, diet) triggers of shared pathways of inflammation across two or more chronic conditions.